Summary：California Budget Proposal Sparks Fear of Higher Private Health Insurance Prices **Introduction**

California Budget Proposal Sparks Fear of Higher Private Health Insurance Prices

**Introduction**
State lawmakers unveiled a revised budget plan this week that includes sweeping changes to how California funds its Medi‑Cal program. While the proposal aims to close a projected $22 billion shortfall, industry analysts warn that the ripple effects could push private health‑insurance premiums upward, affecting millions of residents who rely on employer‑sponsored or individual plans.

**Key Developments**
The budget draft calls for a 1.5 % increase in the state’s hospital provider fee, a measure designed to generate additional revenue for Medi‑Cal. It also proposes tightening eligibility rules for certain supplemental benefits, a move that would shift some costs from the public system to private insurers. In addition, legislators are considering a new tax on high‑cost pharmaceuticals, which could be passed along to consumers through higher drug co‑pays.

Stakeholders from the California Association of Health Plans (CAHP) quickly voiced concern, noting that any reduction in public‑program funding often results in cost‑shifting. “When the state pulls back on payments to hospitals and providers, those entities look elsewhere to recoup losses,” said CAHP spokesperson Lena Martinez. “Private insurers end up absorbing part of that burden, which typically translates into higher premiums for policyholders.”

**Industry Analysis**
Economists point to historical precedents: similar fee adjustments in 2019 and 2021 coincided with 3‑4 % jumps in average private‑plan premiums the following year. The current proposal’s scope is broader, affecting both inpatient and outpatient reimbursement rates. Actuarial models from the UC Berkeley Center for Health Economics suggest that, if enacted as written, the average annual premium for a family plan could rise by $150‑$200, or roughly 4‑5 % above 2024 levels.

Moreover, the proposed pharmaceutical tax raises additional uncertainty. Drug manufacturers have indicated they may offset the levy by increasing list prices, a tactic that could further inflate insurers’ cost structures. Analysts caution that the combined effect might disproportionately impact small‑business plans, which have less negotiating power than large corporate groups.

**Future Outlook**
The budget must still navigate committee hearings and a potential gubernatorial veto before becoming law. Advocacy groups are urging lawmakers